Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Pickles

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Canadian Family Physician Medecin De Famille Canadien|February 6, 2004
What's a man to do? Treatment options for localized prostate cancerTom Pickles
International Journal of Radiation Oncology, Biology, Physics|January 13, 2006
Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapyTom Pickles,
Canadian Family Physician Medecin De Famille Canadien|February 6, 2004
Current status of PSA screening. Early detection of prostate cancerTom Pickles
Future Oncology (London, England)|July 31, 2007
Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factorTom Pickles
The Canadian Journal of Urology|May 5, 2006
The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancerTom Pickles, Alan Pollack
International Journal of Radiation Oncology, Biology, Physics|January 18, 2006
Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoringPaddy Niblock, Tom Pickles,
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 5, 2002
The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000Tom Pickles, Norm Phillips
The Journal of Urology|May 7, 2002
What happens to testosterone after prostate radiation monotherapy and does it matter?Tom Pickles, Peter Graham,
Radiation Oncology (London, England)|May 22, 2007
The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancerPaul A Blood, Tom Pickles
International Journal of Radiation Oncology, Biology, Physics|September 24, 2004
Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient databaseCharmaine Kim-Sing, Tom Pickles,
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Canadian Family Physician Medecin De Famille Canadien|February 6, 2004
What's a man to do? Treatment options for localized prostate cancerTom Pickles
International Journal of Radiation Oncology, Biology, Physics|January 13, 2006
Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapyTom Pickles,
Canadian Family Physician Medecin De Famille Canadien|February 6, 2004
Current status of PSA screening. Early detection of prostate cancerTom Pickles
Future Oncology (London, England)|July 31, 2007
Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factorTom Pickles
The Canadian Journal of Urology|May 5, 2006
The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancerTom Pickles, Alan Pollack
International Journal of Radiation Oncology, Biology, Physics|January 18, 2006
Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoringPaddy Niblock, Tom Pickles,
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 5, 2002
The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000Tom Pickles, Norm Phillips
The Journal of Urology|May 7, 2002
What happens to testosterone after prostate radiation monotherapy and does it matter?Tom Pickles, Peter Graham,
Radiation Oncology (London, England)|May 22, 2007
The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancerPaul A Blood, Tom Pickles
International Journal of Radiation Oncology, Biology, Physics|September 24, 2004
Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient databaseCharmaine Kim-Sing, Tom Pickles,
Pageof 14